Hepatitis C: a brief clinical overview.
Hepatitis C has emerged as an important public health problem that has affected 3.9 million Americans and 170 million people worldwide and is currently the most common indication for orthotopic liver transplantation. The disease, characterized by asymptomatic onset, is often discovered incidentally through blood tests obtained during routine physical examination or before blood donation. Spontaneous recovery occurs in about 20% of patients. Among those who remain chronically infected, an equal percentage progress to cirrhosis within 20 yr, have stable nonprogressive disease, or progress more slowly over 40 to 60 yr. At present, combination therapy with interferon plus ribavirin is the treatment of choice for hepatitis C-infected patients identified as appropriate candidates for therapy. Unfortunately, sustained response rates are only modest, with a lesser response among African Americans, and treatment is associated with a number of side effects. Research studies attempting to improve the response to current therapy, to identify alternative treatments or treatment strategies, and to develop an effective vaccine are ongoing and will hopefully provide us with the ability to better understand and manage hepatitis C.
Strader
D B
DB
Veterans Affairs Medical Center, Washington, D.C. USA.
Seeff
L B
LB
D000998:Antiviral Agents / Q000009:adverse effects / Q000627:therapeutic use*; D044383:Black People; D006528:Carcinoma, Hepatocellular / Q000209:etiology; D018450:Disease Progression; D004359:Drug Therapy, Combination; D006526:Hepatitis C / Q000150:complications / Q000188:drug therapy / Q000453:epidemiology / Q000503:physiopathology; D006801:Humans; D007372:Interferons / Q000009:adverse effects / Q000627:therapeutic use*; D008103:Liver Cirrhosis / Q000209:etiology*; D008113:Liver Neoplasms / Q000209:etiology; D016031:Liver Transplantation; D011634:Public Health; D012075:Remission, Spontaneous; D012254:Ribavirin / Q000009:adverse effects / Q000627:therapeutic use*; D001741:Black or African American
D000998:Antiviral Agents; D012254:Ribavirin; D007372:Interferons